Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly (IRIDIA)
|ClinicalTrials.gov Identifier: NCT00224575|
Recruitment Status : Terminated (End of recruitment period)
First Posted : September 23, 2005
Last Update Posted : March 8, 2016
Despite the effectiveness of beta-blockers and antiplatelet agents for secondary prevention of coronary heart disease, this treatments are underused in the elderly because of diagnosis uncertainty and underuse of efficient treatment.
in a first time, diagnosis reassessment with invasive technique if necessary. in a second time, treatment reassessment.
|Condition or disease||Intervention/treatment|
|Myocardial Ischemia||Other: diagnosis reassessment Other: Diagnosis strategy and subsequent therapeutic reassessment|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||260 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Therapeutical Impact of a Reassessment Strategy in the Diagnosis of Coronary Heart Disease in Elderly|
|Study Start Date :||November 2004|
|Primary Completion Date :||November 2005|
|Study Completion Date :||November 2006|
Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
Other: diagnosis reassessment
Strategy of diagnosis reassessment following a decision tree.
Other Name: no other names to specifiedOther: Diagnosis strategy and subsequent therapeutic reassessment
Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
- therapeutical impact of a reassessment strategy in the diagnosis of coronary heart disease in elderly [ Time Frame: during hospitalization ]
- part link, in the treatment modification, with diagnosis reassessment and the part link with treatment optimization, death and rehospitalization in the subsequent 6 and 12 months [ Time Frame: during hospitalization ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224575
|Paris, France, 75018|
|Principal Investigator:||legrain sylvie||APHP|